Events and Presentations

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events and Presentations

Presentations and Posters
Date Title Format
Apr 10, 2021
Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutations
Mar 05, 2021
38th Annual Miami Breast Cancer Conference: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)
Mar 02, 2021
ESMO TAT Virtual Congress 2021: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
Jan 14, 2021
Current Corporate Presentation
Dec 09, 2020
SABCS: Open-label, phase 1 study to evaluate duration of severe neutropenia after same-day dosing of eflapegrastim in patients with breast cancer receiving docetaxel and cyclophosphamide
Dec 09, 2020
SABCS: Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer
Dec 09, 2020
SABCS: A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy
Upcoming Event
More events are coming soon.
Archived Events
Date Title
Mar 30, 2021
1:30 PM PDT
Feb 11, 2021
4:00 PM EST
Jan 21, 2021
1:00 PM EST
Jan 14, 2021
1:45 PM EST
Jan 11, 2021
6:00 AM EST
Dec 22, 2020
1:30 PM PST
Nov 18, 2020
2:20 PM EST
Nov 16, 2020
2:40 PM EST
Nov 4, 2020
1:30 PM PST
Sep 18, 2020
12:00 AM EDT
Sep 17, 2020
10:40 AM EDT
Sep 14, 2020
2:00 PM EDT
Aug 10, 2020
1:30 PM PDT
Jul 27, 2020
1:30 PM PDT
Jun 22, 2020
9:00 AM EDT
Jun 3, 2020
9:00 AM EDT
May 7, 2020
1:30 PM PDT
Apr 28, 2020
8:30 AM EDT
Apr 27, 2020
2:05 PM EDT